These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21731184)

  • 21. Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses.
    Hunter BG; Duesterdieck-Zellmer KF; Larson MK
    PeerJ; 2015; 3():e889. PubMed ID: 25945303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.
    Denoix JM; Thibaud D; Riccio B
    Equine Vet J; 2003 Jun; 35(4):407-13. PubMed ID: 12880010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and treatment of osteochondritis dissecans of the distal sagittal ridge of the third metacarpal bone.
    Wright IM; Minshall GJ
    Equine Vet J; 2014 Sep; 46(5):585-8. PubMed ID: 24102887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tiludronate therapy for Paget's disease of bone.
    McClung MR; Tou CK; Goldstein NH; Picot C
    Bone; 1995 Nov; 17(5 Suppl):493S-496S. PubMed ID: 8573425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of postmenopausal bone loss by tiludronate.
    Reginster JY; Lecart MP; Deroisy R; Sarlet N; Denis D; Ethgen D; Collette J; Franchimont P
    Lancet; 1989 Dec 23-30; 2(8678-8679):1469-71. PubMed ID: 2574764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy.
    Murakami H; Nakamura T; Tsurukami H; Abe M; Barbier A; Suzuki K
    J Bone Miner Res; 1994 Sep; 9(9):1355-64. PubMed ID: 7529459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys.
    Geusens P; Nijs J; Van der Perre G; Van Audekercke R; Lowet G; Goovaerts S; Barbier A; Lacheretz F; Remandet B; Jiang Y
    J Bone Miner Res; 1992 Jun; 7(6):599-609. PubMed ID: 1414478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia.
    Dumon JC; Magritte A; Body JJ
    Bone Miner; 1991 Dec; 15(3):257-66. PubMed ID: 1773138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a transendoscopic glandular and nonglandular gastric biopsy technique in horses.
    Rodrigues NL; Doré M; Doucet MY
    Equine Vet J; 2009 Sep; 41(7):631-5. PubMed ID: 19927580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
    Roux C
    Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathology of the distal condyles of the third metacarpal and third metatarsal bones of the horse.
    Riggs CM; Whitehouse GH; Boyde A
    Equine Vet J; 1999 Mar; 31(2):140-8. PubMed ID: 10213426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
    Roux C; Gennari C; Farrerons J; Devogelaer JP; Mulder H; Kruse HP; Picot C; Titeux L; Reginster JY; Dougados M
    Arthritis Rheum; 1995 Jun; 38(6):851-8. PubMed ID: 7779130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods.
    Zacharis CK; Tzanavaras PD
    J Pharm Biomed Anal; 2008 Nov; 48(3):483-96. PubMed ID: 18599247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
    Morales-Piga A
    Expert Opin Pharmacother; 1999 Nov; 1(1):157-70. PubMed ID: 11249559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sternal bone biopsy in standing horses.
    Désévaux C; Laverty S; Doizé B
    Vet Surg; 2000; 29(4):303-8. PubMed ID: 10917279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tiludronate: bone pharmacology and safety.
    Bonjour JP; Ammann P; Barbier A; Caverzasio J; Rizzoli R
    Bone; 1995 Nov; 17(5 Suppl):473S-477S. PubMed ID: 8573421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paget's disease of bone treated with a five day course of oral tiludronate.
    Reginster JY; Lecart MP; Deroisy R; Ethgen D; Zegels B; Franchimont P
    Ann Rheum Dis; 1993 Jan; 52(1):54-7. PubMed ID: 8427515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple dose pharmacokinetics of tiludronate in healthy volunteers.
    Schwietert HR; Peeters PA; Dingemanse J; Thiercelin JF; Necciari J; de Bruin H; Jonkman JH
    Eur J Clin Pharmacol; 1996; 51(2):175-81. PubMed ID: 8911885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat.
    Rohanizadeh R; LeGeros RZ; Bohic S; Pilet P; Barbier A; Daculsi G
    Calcif Tissue Int; 2000 Oct; 67(4):330-6. PubMed ID: 11000348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of bisphosphonates in horses - a review].
    Düsterdieck-Zellmer KF
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 2018 Oct; 46(5):323-333. PubMed ID: 30340242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.